According to information from Bloomberg, the nine research firms presently covering Halozyme Therapeutics, Inc. (NASDAQ: HALO) have provided the company with a rating of “Moderate Buy” as their overall consensus for the stock. The research firms gave this rating. Seven market analysts favor buying the stock, while only one endorses the idea of holding on to the stock in one’s portfolio. The $59.63 per share is the 12-month target price established for the stock by analysts who have provided ratings in the previous year. This price was determined by a consensus of the analysts who have provided ratings on the stock in the preceding year.
Several brokerage firms have compiled recent research on Halo, found on those firms’ respective websites. In a report made public on November 9, JMP Securities upgraded their price target on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a rating of “market outperform.” In a research report made public on Wednesday, December 21, Morgan Stanley gave Halozyme Therapeutics the rating of “overweight.” The analysis was written up and posted on the website. The price objective that Morgan Stanley has established for the stock has also been increased and is now projected to be $65.00, up from the previous price objective of $53.00. On October 12, 2018, coverage of Halozyme Therapeutics was first introduced on the website StockNews.com. They recommended that shareholders “hold” their shares of the company. In a research report released on Tuesday, November 22, JPMorgan Chase & Co. increased their price objective for Halozyme Therapeutics from $53.00 to $54.00. In addition, the investment firm rated the company as “overweight,” which is a positive indicator of growth. SVB Leerink lowered their price target on Halozyme Therapeutics from $62 to $61 and gave the company an “outperform” rating in a research report published on January 11. The company’s stock was the subject of both of these amendments to the agreement.
Additionally, on December 2, a Friday, Director Matthew L. Posard sold 10,000 shares of the company’s stock. When the stock was sold, the average price paid for each share was 58.80, which resulted in a total transaction price of $588,000.00. In other words, the average price paid for each share was $58.80. The director is now the direct owner of 125,189 shares of the company, which together have an approximate value of $7,361,113.20 as a result of the transaction. You might find a filing that explains the transaction in greater detail on the Securities and Exchange Commission (SEC) website. On November 15, Chief Financial Officer Nicole Labrosse decided to sell 5,000 of the company’s shares, which brings us to another piece of recent business-related news. The amount of stock sold came to a total of $269,050.00, and the price of $53.81 per share was determined to be the average selling price. Because of the transaction, the chief financial officer now has direct control over 4,045 shares of the company. These shares are worth approximately $217,661.45 in total. The sale was brought to the general public’s attention using a legal filing handed to the SEC. On the website of the SEC, you can locate this particular file. On Friday, December 2, Matthew L. Posard, the company’s director, sold 10,000 shares of the company’s stock. Matthew L. Posard also sold shares of the company on Friday. The total amount obtained from the sale of the shares was $588,000.00, and the price placed on each share was 58.80 cents. Following the completion of the sale, the director will have a total of 125,189 shares of the company; the value of these shares, according to the most recent market price, is $7,361,113.20. Disclosures that are related to the sale might be found in this section of the website. Business insiders were responsible for the sale of a total of 75,000 shares of company stock during the most recent quarter, which resulted in a total price of $4,142,250. 2.30 employees and other company insiders currently hold a percent of the company’s ownership.
Several different hedge funds and institutional investors have recently either increased the amount of HALO they are currently holding in their portfolios or decreased the amount they are currently holding. During the second quarter, Victory Capital Management Inc. grew its holdings of Halozyme Therapeutics stock by 206.7% relative to the previous quarter’s levels. Victory Capital Management Inc. now holds 1,790,044 shares of the biopharmaceutical company’s stock, which are currently valued at $78,761,000 following the purchase of an additional 1,206,368 shares during the most recent quarter. Franklin Resources Inc. increased the percentage of Halozyme Therapeutics stock that is owned by 1,548.8% during the second quarter of the fiscal year. Franklin Resources Inc. has increased its stake in the biopharmaceutical company by purchasing 646,475 shares. This brings the total number of shares the company owns in the biopharmaceutical company to 688,216, which has a value of $30,282,000. During the second quarter, Driehaus Capital Management LLC made a 51.9% investment in Halozyme Therapeutics stock, which increased the company’s ownership percentage. Driehaus Capital Management LLC now holds 1,282,492 shares of the biopharmaceutical company’s stock, with a market value of $56,430,000. This results from the firm’s purchase of an additional 438,429 shares during the relevant period. During the third quarter, the Bank of Montreal Could increase the amount of Halozyme Therapeutics stock owned by 1,979.8%, bringing the total amount of stock it owned to 1,979.8%. Bank of Montreal Can now have a total of 431,396 shares of the biopharmaceutical company following an additional purchase of 410,654 shares during the most recent quarter. These shares are currently valued at $17,450,000. During the third quarter, Mizuho Markets Americas LLC made an additional investment of $14,184,000 in Halozyme Therapeutics by purchasing a new holding in the company. Institutional investors and hedge funds collectively hold a stake in the company equal to 96.32% of the total number of shares outstanding.
Thursday was the first-day trading could begin on the NASDAQ HALO, and the opening price was $52.67. The business has a P/E ratio of 35.35, a beta of 1.23, a PEG ratio of 0.65, and a PEG ratio of 0.65. It is estimated that the company has a market capitalization of $7.12 billion. The company’s price is currently trading at $55.40, higher than its simple moving average for the past 50 days but $48.13 lower than its average price over the past 200 days. There is a debt-to-equity ratio that comes in at 15.37, a quick ratio that comes in at 5.03, a current ratio that comes in at 5.97, and a quick ratio that comes in at 5.03. Over the past 52 weeks, the price of Halozyme Therapeutics has ranged between $31.36 and $59.46, with a high of $59.46 being reached at one point.
On Tuesday, November 8, the most recent quarterly earnings report for Halozyme Therapeutics (NASDAQ: HALO) was made available to the public. The profits generated by the biopharmaceutical business for the quarter came in at $0.70 per share, which was $0.21 more than the average estimate of $0.49 per share. The return on equity for Halozyme Therapeutics was 134.71%, and the net margin for the company was 36.37 percent. Analysts anticipated the company would bring in $187.87 million in revenue from sales during the quarter, but it brought in $208.98 million. Stock market analysts anticipate that Halozyme Therapeutics’ earnings per share will amount to $2.07 in the year 2018, according to the
